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Abstract
Coxiella burnetii and Brucella abortus are two intracellular bacteria
implicated in zoonotic miscarriage. In the present study, C. bur-
netii and B. abortus seroprevalence was compared among women
from London with and without miscarriage. Coxiella burnetii sero-
prevalence was high (4.6%, 95% CI 2.8–7.1) despite the rare
apparent exposure of this urban population. Only two patients
exhibited anti-B. abortus antibodies. As a result of the risk of
chronic Q fever with endocarditis and/or hepatitis, the mode of
Coxiella burnetii infection in this population merits further
investigation.
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Coxiella burnetii, the agent of Q fever, is an intracellular bac-
terium that may cause systemic infections in humans. Acute
Q fever is often asymptomatic or manifests only as an
inﬂuenza-like unrecognized illness [1,2]. It may also present
as hepatitis or atypical pneumonia. Blood culture-negative
endocarditis, vascular infections, osteoarticular involvement
and chronic liver diseases are the main clinical pictures of
chronic Q fever, which represents a rare complication of
acute Coxiella infection [1]. Domestic animals and pets are
the most frequent source of Coxiella infections in humans
[1]. Brucella abortus is another zoonotic intracellular bac-
terium that may cause systemic infection. This infection fre-
quently presents as a sustained fever (91% of cases), rarely
associated with hepatomegaly (17%), splenomegaly (16%) and
lymphadenopathy (6%) [3,4].
Both bacterial species have been associated with human
miscarriage [1–4]. Coxiella burnetii, when contracted during
human pregnancy, may result in a fatal outcome [5–9]. How-
ever, other studies performed in more than 12 000 pregnant
women failed to conﬁrm an association of Coxiella seroposi-
tivity with pregnancy outcome [10]. The reproductive system
is the second most common site of brucellosis, being associ-
ated with a substantial risk of miscarriage during pregnancy
[11,12].
The main aim of the present study was to evaluate C. bur-
netii and B. abortus seroprevalence among a population of
pregnant women in a non-endemic area. In addition, the role
of Coxiella and Brucella as agents causing miscarriage was also
assessed.
Sera were obtained from women attending the Recurrent
Miscarriage Clinic of St Mary’s Hospital, London. The 438
sera had previously been investigated for Waddlia chondrophil-
a and other Chlamydiae [13]. This allowed the assessment of
any serological cross-reactivity among C. burnetii, B. abortus
and several other previously studied intracellular bacteria,
which are listed in Table 1.
Sera were tested for the presence of antibodies directed
against C. burnetii using indirect immunoﬂuorescence [14].
Brieﬂy, sera were screened using an indirect immunoﬂuores-
cence assay (IFA) at a 1/50 dilution with C. burnetii phase I
and II antigens (strain Nine Miles, kindly provided by
W. Burgdorfer, Rocky Mountain Laboratories, Hamilton, MT,
USA). We used ﬂuorescein isothiocyanate goat anti-human
speciﬁc IgG conjugate (bioMe´rieux, Marcy-l’Etoile, France).
Positive sera were then serially two-fold diluted starting at
1/20.
Serological B. abortus diagnosis was established using the
Wright’s tube agglutination test (Brucella Antigen, Sanoﬁ
Diagnostics, Marnes-la-Coquette, France). Antibody reactivity
against Toxoplasma gondii was assessed using a commercial
latex agglutination kit, Toxo-Screen DA (bioMe´rieux). Preva-
lence and p values were calculated using STATA software
(StataCorp, College Station, TX, USA).
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Among the 438 women enrolled in the study [13], 20
(4.6%, 95% CI 2.8–7.1) were positive for C. burnetii phase II
IgG antibodies. None was positive for C. burnetii phase I IgG
antibodies. Only two (0.5%, 95% CI 0.1–1.7) also exhibited
IgM antibodies against C. burnetii. No statistical differences
were observed between C. burnetii IgG seroprevalences in
women with sporadic (1/69, 1.4%, 95% CI 0.1–8.1, p 0.188)
or recurrent miscarriage (8/200, 4%, 95% CI 1.7–7.9%,
p 0.346) compared to controls (11/169, 6.5%, 95% CI
3.2–11.6).
The demographic characteristics and potential risk fac-
tors for IgG seropositivity for C. burnetii are shown in
Table 1. Although outbreaks of Q fever in humans result
from inhalation of aerosols from infected parturient ani-
mals, the frequency of animal contacts was similar between
women who were C. burnetii IgG positive and those who
were C. burnetii IgG negative. Toxoplasma gondii seropreva-
lence was similar in women with and without anti-Coxiella
antibodies, suggesting that Coxiella and the protozoon do
not have similar modes of transmission (i.e. contact with
cats). One healthy control woman, who was a cat and
dog owner, and one woman with recurrent miscarriage
were C. burnetii IgM positive. Both were UK-born
Caucasians.
Serological cross-reactions with zoonotic (W. chondrophila,
Parachlamydia acanthamoebae, Chlamydophila psittaci, B. abor-
tus) and human (Chlamydia trachomatis) potential agents of
miscarriage were also studied. None of these organisms
showed evidence of cross-reaction with Coxiella.
The serum of only two women (0.5%, 95% CI 0.1–1.6)
contained antibodies directed against Brucella. Both were
immigrants from Sudan. One was healthy, with an at-term
pregnancy, whereas the other recurrently miscarried, a total
of ﬁve times, and no other aetiology of miscarriage was
identiﬁed.
In conclusion, exposure to C. burnetii is common and
exposure to B. abortus is uncommon in women in London,
with a seroprevalence of 4.6% and 0.5%, respectively.
Coxiella burnetii serosurveys, mainly conducted in endemic
areas, are difﬁcult to compare because of the different meth-
ods and cut-off values employed [2]. In the present study, an
IgG anti-phase II C. burnetii cut-off of 1/50 was chosen, as
recommended elsewhere [1]. Surprisingly, the overall Coxiella
IgG seroprevalence of 4.6% observed in this urban popula-
tion from an area considered to be non-endemic was similar
to the seroprevalence reported from endemic areas [1]. In
an endemic area of France, 0.15% of 12 716 pregnant
women had serum anti-Coxiella IgG titres ‡1/100 [10]. In an
TABLE 1. Characteristics of patients
according to their Coxiella burnetii
serostatus
Coxiella negative
(n = 418)
Coxiella positive
(n = 20) p value*
Age
Median (IQR) 33 (28–38) 33 (29–37) 0.843
Number of pregnancy
1 115 (27.5%) 7 (35%) 0.239
2 77 (18.4%) 1 (5%)
>2 226 (54.1%) 12 (60%)
Parity
0 159 (38%) 3 (15%) 0.067
1 175 (41.9%) 10 (50%)
2 50 (12%) 4 (20%)
>2 34 (8.1%) 3 (15%)
Miscarriages
Early £12 weeks 242 (57.9%) 9 (45%) 0.355
Late >12 weeks 61 (14.6%) 3 (15%) 1.000
Stillbirth >24 weeks 15 (3.6%) 0 (0%) 1.000
Ethnicity
White 235 (56.2%) 11 (55%) 1.000
Black 63 (15.1%) 4 (20%) 0.526
Asian 78 (18.7%) 5 (25%) 0.557
Other 42 (10.5%) 0 (0%) 0.241
Born in the UK 224 (53.6%) 10 (50%) 0.821
Contact with animals 106 (25.4%) 4 (20%) 0.793
Cat 57 (13.6%) 3 (15%) 0.745
Dog 46 (11%) 3 (15%) 0.480
Additional serologies
Waddlia chondrophila (IgG‡1/64) 93 (22.3%) 4 (20%) 1.000
Parachlamydia (IgG ‡1/64) 7 (1.7%) 0 (0%) 1.000
Chlamydia trachomatis (IgG ‡1/50) 61 (14.6%) 2 (10%) 0.752
Chlamydia pneumoniae (IgG ‡1/64) 187 (44.7%) 12 (60%) 0.250
Chlamydia psittaci (IgG ‡1/64) 26 (6.2%) 0 (0%) 0.622
Brucella abortus (Ig ‡1/20) 2 (0.48%) 0 (0%) 1.000
Toxoplasma gondii (Ig ‡1/20) 96 (22.3%) 4 (20%) 1.000
IQR, interquartile range.
*Fisher’s exact chi-squared test.
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endemic area of Canada, 3.8% (291/7658) of pregnant
women exhibited a phase II titre ‡1/32 [7]. Moreover,
among 200 healthy Japanese pregnant women, only four (2%)
had anti-Coxiella IgG antibodies ‡1/16 [9].
Q fever is frequently under-diagnosed because of the
intracellular nature of C. burnetii, and because as many as
60% of infections remain asymptomatic [1]. Among 2% of
patients requiring hospitalization, approximately 10% develop
chronic Q fever, including endocarditis and/or chronic hepa-
titis [2,15]. Considering the 4.5% prevalence observed in the
present study, we estimate that, among the 7.5 million inhab-
itants of London [16], 300 000 have serological evidence of
prior Coxiella infection, 6000 will require hospitalization, and
600 may develop chronic Q fever if left untreated.
The present study failed to show an association between
Coxiella-positive serology and contact with domestic animals.
Other modes of transmission, including person-to-person
contact [2], or via arthropod exposure [1], raw milk or
Coxiella-infected amoebae in water [17,18], should be inves-
tigated in an attempt to understand infection with Coxiella
in an urban area such as London. We found no association
between Coxiella-positive serology and miscarriage. How-
ever, the small sample size limits conclusions concerning
this issue. The present study also showed the absence of
serological cross-reactivity between Coxiella and other
agents of miscarriage, such as W. chondrophila. Only two
women exhibited evidence of previous infection with
Brucella spp., which is consistent with previously obtained
data [3,4]. Q fever might be under-reported in London. As
a result of the considerable morbidity associated with Q
fever, physicians should be aware of the relatively common
exposure to this bacterium, even in urban, non-endemic
settings.
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